Results 51 to 60 of about 82,830 (185)

Focal Hypertrichosis during Topical Tacrolimus Therapy for Vitiligo: A Case Report

open access: yesCase Reports in Dermatology
Introduction: Tacrolimus is widely used in treating vitiligo. Drug-induced hypertrichosis is a well-known side effect of cyclosporine. It is less commonly associated with tacrolimus or with topical calcineurin inhibitors.
Lingyu Mao   +3 more
doaj   +1 more source

Antifungal activities of tacrolimus in combination with antifungal agents against fluconazole-susceptible and fluconazole-resistant Trichosporon asahii isolates

open access: yesBrazilian Journal of Infectious Diseases, 2016
The antifungal activity of tacrolimus in combination with antifungal agents against different fungal species has been previously reported. Here we report the in vitro interactions between tacrolimus and amphotericin B, fluconazole, itraconazole, and ...
Thaís Felli Kubiça   +6 more
doaj   +1 more source

Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients – a case series with four patients

open access: yesBMC Nephrology, 2023
Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider   +5 more
doaj   +1 more source

The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation : Post-Hoc Analyses of the DIAMOND Study [PDF]

open access: yes, 2019
Background: The DIAMOND study of de novo liver transplant patients showed that prolonged-release tacrolimus exposure in the acute post-transplant period maintained renal function over 24 weeks of treatment.
Trunecka, Pavel   +5 more
core   +1 more source

Individualized dosing parameters for tacrolimus in the presence of voriconazole: a real-world PopPK study

open access: yesFrontiers in Pharmacology
ObjectivesSignificant increase in tacrolimus exposure was observed during co-administration with voriconazole, and no population pharmacokinetic model exists for tacrolimus in renal transplant recipients receiving voriconazole.
Yi-Chang Zhao   +16 more
doaj   +1 more source

Safety and Efficacy of Infusional Perioperative Tacrolimus Therapy in Crohn’s Disease Patients Undergoing Intestinal Resection

open access: yesInflammatory Intestinal Diseases
Introduction: Perioperative optimization of Crohn’s disease (CD) patients is mandatory in order to ensure favorable outcomes and limit perioperative morbidity such as anastomosis-related complications.
Maximilian Beck   +7 more
doaj   +1 more source

Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients

open access: yes, 2023
Shuang Liang,1 Yan-Jun Liang,1 Zhao Li,2 Yong Wang,1 Xin-Ru Guo,1 Chao-yang Zhang,1 Chun Zhang,1 Jie Wu,1 Xiao-Long Wang,1 Yi-Sha Li,1 Guang-Yan Cai,1 Xiang-Mei Chen1 1Department of Nephrology, First Medical Center of Chinese PLA General Hospital ...
Liang S   +11 more
core  

Streptomyces tsukubaensis as a new model for carbon repression: transcriptomic response to tacrolimus repressing carbon sources [PDF]

open access: yes
[EN] In this work, we identified glucose and glycerol as tacrolimus repressing carbon sources in the important species Streptomyces tsukubaensis. A genome-wide analysis of the transcriptomic response to glucose and glycerol additions was performed using ...
Rodríguez García, Antonio   +5 more
core   +1 more source

Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. [PDF]

open access: yes, 2012
The immunosuppressive drugs used to prevent the rejection of transplanted organs have a narrow therapeutic index. Under treatment results in episodes of rejection leading to either damage or loss of the organ. Over immunosuppression increases the risk of
MacPhee IA   +3 more
core   +1 more source

Topical tacrolimus : efficacy and tolerability

open access: yes, 2013
Tacrolimus, formulated as a 0.1% or 0.03% ointment, is the first topical immunosuppressant to receive widespread regulatory approval. Currently, it is only approved for the second-line treatment of moderate or severe atopic eczema in adults and children >
Lee, Frederick J.   +1 more
core  

Home - About - Disclaimer - Privacy